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Nitric oxide (NO) maintains cardiovascular health by activating soluble guanylate cyclase
(sGC) to increase cellular cGMP levels. Cardiovascular disease is characterized by
decreased NO-sGC-cGMP signaling. Pharmacological activators and stimulators of sGC
are being actively pursued as therapies for acute heart failure and pulmonary hypertension.
Here we review molecular mechanisms that modulate sGC activity while emphasizing a
novel biochemical pathway in which binding of the matricellular protein thrombospondin-1
(TSP1) to the cell surface receptor CD47 causes inhibition of sGC. We discuss the
therapeutic implications of this pathway for blood flow, tissue perfusion, and cell survival
under physiologic and disease conditions.
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INTRODUCTION
Cardiovascular disease is the number one cause of death world-
wide and remains a burdensome health problem. Understanding
the underlying molecular mechanisms of cardiovascular disease
will provide valuable information for the design of novel drugs
for pharmacological therapies.
As a central player of the canonical NO-sGC-cGMP pathway,
sGC controls important physiological functions such as smooth
muscle relaxation, platelet aggregation, and hemostasis (Isenberg
et al., 2009b). Hence, sGC activity is a primary means of con-
trolling acute and chronic blood flow. The gaseous molecule
NO directly activates sGC and increases the production of the
signaling molecule 3′,5′-cyclic GMP (cGMP) from GTP several
hundred fold (Arnold et al., 1977). Second messenger cGMP, in
turn, targets the contractile apparatus of arterial smooth muscle
cells and adhesive pathways of platelets and inflammatory cells
to promote vasodilation and disadhesion/disaggregation (Murad
et al., 1985; Munzel et al., 2003). Decreased NO bioavailabil-
ity and sGC oxidation lead to inefficient sGC activation and
lower cGMP output, which are associated with and directly con-
tribute to cardiovascular diseases including ischemic heart dis-
ease, decompensated heart failure, ischemia reperfusion injury,
visceral organ transplant failure, stroke, pulmonary and sys-
temic hypertension, and atherosclerosis (Murad et al., 1978; Lucas
et al., 2000; Loscalzo, 2001; Voetsch et al., 2004; Mitrovic et al.,
2011).
Here, we first review molecular factors that modulate sGC
activity under healthy and diseased conditions. The sGC enzyme
is tightly regulated by its oligomeric and conformational state,
endogenous and pharmacological ligands, post-translational
modification, the cellular redox environment, sub-cellular local-
ization, and protein-protein interactions. We then highlight the
role of matricellular protein signaling, in particular TSP1, in
inhibiting sGC activity and its potentially important implications
for angiogenesis and blood flow.
THE NO-sGC-cGMP PATHWAY IN THE CARDIOVASCULAR
SYSTEM
Physiologic (low dose) NO is formed via two primary pathways.
NO is generated when endothelial nitric oxide synthase (eNOS)
is activated by Ca2+/calmodulin binding in response to exter-
nal stimuli including laminar blood flow and hormonal cues,
such as vascular endothelial growth factor (VEGF) (Zhao et al.,
1999). Another source of NO arises from the reduction of dietary
nitrates to nitrite and eventually NO. This latter source of NO is
eNOS-independent and is likely relevant in conditions of hypoxia
(reviewed in Lundberg et al., 2008; Weitzberg and Lundberg,
2013). The half-life of NO under physiological conditions is
roughly 0.1 s (Kelm and Schrader, 1990) and its affinity for sGC is
in the picomolar to low nanomolar range (Stone and Marletta,
1996; Tsai et al., 2012a), indicating that sGC is highly respon-
sive to low NO concentrations. NO binding to sGC increases
enzyme activity several hundred fold by inducing a transition
from a basal to an activated state (Moncada and Higgs, 1993).
Downstream of sGC, cGMP interacts with two different classes of
effector molecules to achieve vascular smooth muscle relaxation:
cGMP-dependent kinase (cGKs) and phosphodiesterases (PDEs)
(Lincoln and Cornwell, 1993; Wu et al., 2000). The final cellular
concentration of cGMP depends on the rate of production by sGC
and the rate of hydrolysis by cGMP PDEs.
sGC IS A MODULAR HETERODIMERIC ENZYME
Cytoplasmic sGC exists as a heterodimer of an α and a β sub-
unit. Heterodimerization is crucial for catalytic activity of sGC
since both subunits contribute residues to the active site that is
formed at the interface of the catalytic domain (Buechler et al.,
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1991). However, homodimers exist in vitro and cell lysates (Zabel
et al., 1999) and certain functions have been attributed to a single
subunit in vivo (Gao et al., 2013). It has been further proposed
that homo- and heterodimerization may regulate activity in vivo
and that inactive homodimer pools may regulate the formation
of active and activatable heterodimers within the cell (Zabel et al.,
1999; Zhou et al., 2008).
Mammals have two different isoforms of each sGC subunit.
The α1β1 sGC heterodimer is the best characterized and is the
predominant form in the cardiovascular system (Gupta et al.,
1997; Mergia et al., 2003). The regulatory N-terminal domain of
the β subunit harbors a heme prosthetic group that is the pri-
mary NO binding site of the enzyme (Gerzer et al., 1981). The
high-resolution three dimensional structure of sGC is unknown
but crystal structures of individual domains or domain homologs
have been determined for the HNOX domain (Nioche et al., 2004;
Pellicena et al., 2004; Ma et al., 2007; Olea et al., 2008; Erbil
et al., 2009; Martin et al., 2010; Olea et al., 2010; Weinert et al.,
2010, 2011; Winter et al., 2011), the HNOXA domain (Ma et al.,
2008; Purohit et al., 2013), the CC domain (Ma et al., 2010),
and the GC domain (Rauch et al., 2008; Winger et al., 2008;
Allerston et al., 2013; Seeger et al., 2014). Recent studies sug-
gest how these domains assemble in space to form the full-length
enzyme. Winger et al., first suggested that βHNOX directly binds
to and inhibits the cyclase domains (Winger and Marletta, 2005).
Later studies supported this hypothesis, and further showed close
proximity of the βHNOX and cyclase domains (Haase et al., 2010;
Underbakke et al., 2013; Busker et al., 2014). Recent studies also
demonstrated that αHNOX and αHNOXA maintain the βHNOX
in an inhibited state that is released upon NO/activator binding
thus leading to cyclase activation (Fritz et al., 2013; Purohit et al.,
2014). Complementing this model of auto-inhibition, a compre-
hensive regulation mechanism was recently proposed whereby
the activity of sGC is fine-tuned by distinct domain interac-
tions that either inhibit or promote an optimal conformation of
the active center (Seeger et al., 2014). Low-resolution electron
microscopy (EM) data on rat sGC confirm most previous obser-
vations regarding the domain arrangement of sGC (Campbell
et al., 2014). The EM envelope shows two distinct lobes compris-
ing the HNOX and HNOXA domains at the N-terminus and the
GC domains at the C-terminus. These two lobes are connected
by a parallel CC domain linker. The reconstruction suggests that
the full-length enzyme is highly flexible around the HNOXA-CC
and CC-GC domain borders and explore a wide range of con-
formational space. Substrate and/or NO binding to the enzyme
do not seem to stabilize specific conformations or restrict the
movement observed in the apo enzyme. The lack of observation
of distinct conformations that may correspond to the basal and
activated state of the enzyme leads to the conclusion that domain-
domain interactions as well as small intra-molecular changes
account for the transition between the two activity states of sGC
(Campbell et al., 2014; Seeger et al., 2014). Despite these signif-
icant advances, the exact mechanism by which sGC propagates
the NO activation signal from the regulatory N-terminus to the
catalytic C-terminus of the protein remains elusive (reviewed in
Derbyshire and Marletta, 2012; Fritz et al., 2013; Underbakke
et al., 2013).
sGC ACTIVATION BY NO
When NO binds to the β subunit heme of sGC, a complex is
formed in which both NO and β-His105 axially ligate the Fe2+
atom (Stone et al., 1995; Stone and Marletta, 1996; Zhao et al.,
1999; Goodrich et al., 2010). This NO binding event leads to
elongation and possibly breakage of the Fe-His105 bond and
formation of the NO-bound sGC species (Dierks et al., 1997).
Subsequent structural rearrangements in the enzyme lead to a
100–200 fold increase in enzyme activity (Wedel et al., 1994;
Russwurm andKoesling, 2004; Cary et al., 2005; Pal and Kitagawa,
2010).
The first NO binding event is instantaneous (Stone and
Marletta, 1996). Subsequent decay of the NO-sGC-His105 com-
plex can form two catalytically distinct species: a high- and a
low-activity NO-sGC (Russwurm and Koesling, 2004; Cary et al.,
2005; Derbyshire et al., 2008). In conditions of excess NO or sto-
ichiometric NO in the presence of substrate or product, the fully
active NO-sGC species is formed (Russwurm and Koesling, 2004;
Cary et al., 2005; Tsai et al., 2012a). In conditions of stoichio-
metric amounts of NO in the absence of substrate or products,
a highly active NO-sGC species is formed that then rapidly
degrades into a low-activity NO-sGC species (characterized by
cGMP formation levels only a few fold above the basal level) (Tsai
et al., 2011).
POTENTIAL MECHANISMS OF sGC DESENSITIZATION
Interestingly, once exposed to NO, sGC decreases its cGMP out-
put during subsequent NO exposure—a process termed desensiti-
zation (Mulsch et al., 1988; Schroder et al., 1988). Three potential
mechanismsmay be responsible for sGC desensitization: (i) heme
oxidation (Schrammel et al., 1996; Zhao et al., 2000), (ii) heme
nitrosylation by a second NO molecule (Tsai et al., 2011), or
(iii) S-nitrosation of Cys residues in close proximity to the heme
pocket (Sayed et al., 2007; Fernhoff et al., 2009; Mayer et al.,
2009; Baskaran et al., 2011). The deactivation of sGC—the tran-
sition from the activated to the basal/sensitized state—is not as
well understood as the process of sGC activation. Whether the
dissociation of NO from the enzyme directly leads to deactiva-
tion remains controversial: in vitro, deactivation occurs within
minutes after NO dissociation (Kharitonov et al., 1997; Brandish
et al., 1998); in contrast, in vivo, NO dissociation leads to enzyme
deactivation within seconds (Bellamy et al., 2000). sGC stimula-
tors slow down sGC deactivation (Russwurm et al., 2002). Other
sGC activity regulators such as nucleotides do not appear to influ-
ence the deactivation mechanism (Margulis and Sitaramayya,
2000; Russwurm et al., 2002).
NUCLEOTIDES, SMALL MOLECULES, AND CALCIUM INHIBIT
sGC ACTIVITY AND ACTIVATION
Several small molecules, including heme-oxidizing agents and
calcium have been shown to inhibit sGC activity (Figure 1).
The nucleotides ATP, UTP, and CTP have been shown to
be competitive, allosteric, or mixed-type inhibitors of sGC
(Brandwein et al., 1982; Gille et al., 2004; Ruiz-Stewart et al.,
2004; Chang et al., 2005). Heme-oxidizing molecules such
as ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one),
NS2028 (8-bromo-4H-2, 5-dioxa-3, 9b-diaza-cyclopenta[a]
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FIGURE 1 | Matricellular TSP1 via CD47 restricts NO-sGC-cGMP
signaling. TSP1 inhibits the sGC-cGMP axis via multiple mechanisms to
circumvent its beneficial effects. Upstream of sGC-cGMP, TSP1 engages
CD47 altering cell calcium flux and VEGF receptor signaling to inhibit
eNOS-stimulated NO production. TSP1 via CD36 also inhibits eNOS
stimulation in endothelial cells by limiting essential free fatty acid uptake (not
pictured). TSP1 through CD47, and SIRP-α, stimulates pathologic superoxide
production which catabolizes NO. Increased ROS can be expected to alter
adversely key protein residues further inhibiting the sGC-cGMP pathway. At
the levels of sGC, TSP1 via CD47 directly inhibits sGC and inhibits its
sensitivity to NO and non-NO activation. TSP1 can also stimulate increased
calcium flux in certain cells which inhibits sGC activation in T cells. TSP1 via
CD47 also inhibits synthesis of H2S which in turn regulates sGC. Extracellular
β-amyloid binds to CD36 and cross talk with CD47 inhibits NO and non-NO
activation of sGC. Finally, in vascular smooth muscle cells and platelets TSP1
via CD47 inhibits activation of cGMP-dependent protein kinase.
naphthalen-1-one), LY8358369, and methylene blue (Gruetter
et al., 1981) inhibit sGC activation by oxidizing its heme moiety
(Garthwaite et al., 1995). Heme oxidation is detrimental to
enzyme activity for two reasons: (1) Ferric heme has a lower
affinity to NO than ferrous heme (Schrammel et al., 1996; Zhao
et al., 2000; Fritz et al., 2011), thus NO is unable to activate
oxidized sGC as effectively, and (2) Oxidized ferric heme readily
dissociates from the enzyme, rendering it insensitive to NO
(Fritz et al., 2011). Additionally, heme-free sGC is prone to
degradation (Stasch et al., 2006), exacerbating the effect of heme
oxidation in vivo. The anti-malaria drug artemisinin inhibits
NO-stimulated sGC activity with no effect on basal activity
(Piatakova and Severina, 2012), although the mechanism of
inhibition is unknown. Finally, calcium directly inhibits basal
and activated sGC in vivo and in vitro (Parkinson et al., 1999;
Serfass et al., 2001; Kazerounian et al., 2002; James et al., 2009).
sGC PHOSPHORYLATION AND DEPHOSPHORYLATION
Basal and stimulated sGC activity can both be regulated
by post-translational modifications including phosphorylation
and dephosphorylation. Depending on the identity of the
kinase/phosphatase, sGC can be either inhibited or stimulated
via the addition/removal of a phosphate group to/from a Ser,
Thr, or Tyr residue. Phosphorylation (Murthy, 2004; Zhou et al.,
2008) and dephosphorylation (Ferrero et al., 2000) of the cGMP
target PKG, and phosphorylation of the protein tyrosine kinase
c-SRC (Meurer et al., 2005; Murthy, 2008) have been shown to
be inhibitory (Figure 1). Phosphorylation by protein kinase C
(PKC) (Louis et al., 1993) and protein kinase A (PKA) (Zwiller
et al., 1981) have been reported to have sGC activating effects.
Phosphorylation by Ca2+/calmodulin-dependent protein kinase
(CaMK) further mediates membrane localization of sGC in
cardiomyocytes (Agullo et al., 2005), which may influence the
activity state of the enzyme as well.
sGC THIOL OXIDATION
Human sGC contains 37 Cys residues: 14 in the β and 23 in the α
subunit. Consequently, S-nitrosation has been postulated to affect
both activation (Fernhoff et al., 2009) and desensitization (Sayed
et al., 2008). It was hypothesized that full activation of sGC may
only be achieved when a second NO molecule (in addition to the
first heme-bound NO) S-nitrosates an unidentified Cys residue
on the protein surface (Fernhoff et al., 2009). Biochemical, crys-
tallographic, and mutagenesis studies reveal that S-nitrosation
causes NO desensitization of the ferric form of sGC (Sayed et al.,
2007). sGC can also be inhibited via mixed disulfide formation of
naturally occurring compounds such as cystamine and oxidized
coenzyme A (Brandwein et al., 1981). Depletion of the cellular
reducing equivalents NADPH and glutathione may cause fur-
ther sGC thiol oxidation and decreases in enzyme activity (Wu
et al., 1992;Mingone et al., 2006). Additional evidence reveals that
sGC and protein disulfide isomerase (PDI) co-localize in smooth
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muscle cells (Heckler et al., 2013). In vitro data from COS-7 cell
lysates suggests that a disulfide bond exchange between PDI and
sGC decreases NO-stimulated activity. The exact mechanism and
identification of putative Cys residues involved in this process
is the subject of current investigation. Combined, these obser-
vations corroborate the importance of the redox state of Cys
residues in modulating sGC enzyme activity.
OXIDATIVE STRESS IN CARDIOVASCULAR DISEASES
DOWNREGULATES sGC AND eNOS EXPRESSION
In contrast to the pharmacologic effects of chemical oxidizing
agents such as ODQ, the oxidative cellular environment found in
many chronic cardiovascular diseases (Cai and Harrison, 2000)
also promotes loss of heme in sGC with a subsequent decrease
in sGC activity (Wu et al., 1992). These naturally occurring
forms of oxidized sGC not only have a lower affinity to NO
but are also prone to proteolysis after losing the non-covalently-
bound, oxidized heme (Stasch et al., 2006; Fritz et al., 2011).
Exacerbating the effect in cardiovascular disease, sGC and eNOS
protein expression is down-regulated in ageing cells while the
concentration of the reactive oxygen species (ROS) superox-
ide anion increases, scavenging available NO (Bauersachs et al.,
1998). NO and ROS not only regulate sGC activity at the protein
level but also influence sGC gene expression at the transcriptional
and translational level (Gerassimou et al., 2007). This is relevant
in light of new work (discussed below) that describes regulation
of NO and ROS by matricellular proteins.
sGC LOCALIZATION MODULATES ENZYMATIC ACTIVITY
Localization of sGC from the cytosol to the membrane may
influence enzyme activity through changes in the redox micro-
environment and bioavailability of NO. sGC localizes to the
plasma membrane in heart tissue in a calcium-dependent fashion
(Zabel et al., 2002). Enzyme that fails to localize to the caveolae is
more prone to oxidation and consequent heme loss (Linder et al.,
2005; Tsai et al., 2012b). Additionally, sGC is more efficiently
activated when associated with the membrane because of higher
NO availability at that locale. In the cytosol of cardiac myocytes,
NO is readily scavenged by myoglobin (Wykes and Garthwaite,
2004). Hence, cellular micro-domains are crucial for sGC func-
tion. The protein AGAP1 (ArfGAP protein with a GTPase-like
domain, Ankyrin repeats, and a pleckstrin homology domain)
may regulate the intracellular distribution of sGC and thus the
local delivery of cGMP in mammalian cells (Meurer et al., 2004).
The G-protein regulator LGN [Leu-Gly-Asn repeat-enriched pro-
tein; also called GPSM2 (G-protein signaling modulator-2) and
its homolog AGS3 (activator of G-protein signaling 3)-like] both
inhibit sGC activity in cell lysates likely by regulating its cellular
localization. Hsp70 and sGC interact in COS-7 cells and co-
localization to the plasma membrane has been shown (Balashova
et al., 2005). In the central nervous system, the post-synaptic
density protein 95 (PSD-95) interacts with the α2β1 isoform of
sGC (Russwurm et al., 2001) and targets sGC to the postsynap-
tic membrane (Brenman et al., 1996). Additionally, in studies
employing co-immunoprecipitation, the α1β1sGC enzyme forms
a trimeric complex with heat-shock protein 90 (hsp90) and eNOS
that localizes to the plasma membrane in aortic smooth muscle
cells (Venema et al., 2003). Further confirmation with additional
methodologies will be required to verify these results. Recently
hsp90 was shown to directly interact with heme-depleted sGC
and aid heme incorporation using its inherent ATPase chaperone
activity (Ghosh and Stuehr, 2012). It is important to emphasize
that most of sGC’s interactions with other proteins have only
been shown in vitro or in cell culture using immunoprecipitation
and yeast-to-hybrid assays, and lack confirmation in vivo. Further
research must provide a physiological context for these observed
interactions.
PHARMACOLOGICAL ACTIVATION OF sGC IN
CARDIOVASCULAR DISEASES: NO DONORS, STIMULATORS,
AND ACTIVATORS
Therapeutic agents that target sGC can be divided into three
categories: NO donors, sGC stimulators, and sGC activators.
Stimulators of sGC synergize and sensitize sGC for activation
with NO; activators on the other hand are NO- and heme-
independent. NO donor treatment is associated with side effects
that include non-specific interactions of NO with other cellular
proteins and tolerance development. Thus, there is a need for acti-
vators as well as stimulators to directly target sGC and increase
cellular cGMP levels in disease states. A prominent sGC stim-
ulator is BAY63-2521 (Riociguat). Riociguat raises the potency
of sGC activation by NO and has been approved for the treat-
ment of pulmonary arterial hypertension (Ghofrani et al., 2013).
The mode of binding of Riociguat, and other stimulators, to sGC
is unknown (Schermuly et al., 2011). In contrast, BAY58-2667
(Cinaciguat)—an sGC activator—works in a NO- and heme-
independent manner (Chester et al., 2011; Erdmann et al., 2013)
by replacing the heme moiety (Martin et al., 2010). The devel-
opment of hypotension in patients with acute decompensated
heart failure of the Phase IIb clinical trial likely rendered this
compound unsuitable for widespread application in this con-
dition (Erdmann et al., 2013). Other heme-replacing activators
are BAY 60-2770 and HMR1766 (Ataciguat) (Mendes-Silverio
et al., 2012; Kumar et al., 2013). While the mode of bind-
ing of sGC activators has been structurally characterized, the
binding sites of sGC stimulators remain unknown. Recent evi-
dence, however, suggests that the experimental stimulator YC-1
binds to the βHNOX and/or βHNOXA domains (Purohit et al.,
2014).
MATRICELLULAR PROTEINS AND EMERGING sGC
REGULATORY MECHANISMS
Matricellular proteins are so named because they bind to both
structural proteins, such as collagen within the extracellular
matrix, and to cells via cell membrane receptors (Lawler and
Lawler, 2012). In this capacity they modulate both cellular and
matrix processes (Bornstein, 2009). Matricellular proteins them-
selves do not have known structural function, but they can alter
the production and maintenance of matrix directly and through
effects upon cells within the matrix (Mosher and Adams, 2012).
The role of matricellular proteins in regulating cardiovascular
events has been primarily defined in terms of angiogenesis—the
process of new blood vessel formation. Angiogenesis (Isenberg
et al., 2005a) is required for the healing response that is initiated
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by wounding and requires days to weeks complete (Miller et al.,
2009). Consequently, the kinetics of matricellular signaling, as it
relates to the vasculature and blood flow, have been conceptual-
ized as subacute and chronic. Matricellular proteins have a new-
found role in regulating acute cardiovascular events including
vessel contractility and blood flow. These insights have stemmed
from the recently discovered ability of a prototypical member of
this class of proteins to rapidly and redundantly limit the canon-
ical NO signaling pathway in vitro and in vivo (Isenberg et al.,
2009b) (Figure 1).
TSP1 IS A PROTOTYPICAL MATRICELLULAR PROTEIN
One of the first identified matricellular proteins that has
served as a prototypical example of this class of molecules is
thrombospondin-1 (TSP1) (Baenziger et al., 1971; Lawler et al.,
1978). TSP1 is the most widely studied member of the throm-
bospondin family (Bornstein et al., 1991). Five thrombospondins
are found in vertebrates (Adams and Lawler, 2011), and of
these TSP1 and thrombospondin-2 (TSP2) function as regu-
latory matricellular proteins in the vascular system. TSP1 is
known to interact with at least nine separate cell receptors.
TSP1 contains a linear arrangement of functional domains and
assembles into a trimeric complex via disulfide bonds near the
N-terminus. The N-terminal domain, the central type 1 repeats
and C-terminal domain of TSP1 interact with distinct receptors
on vascular cells to modulate cell viability (Guo et al., 1997),
growth (Taraboletti et al., 1990; Bagavandoss et al., 1993), motil-
ity (Vogel et al., 1993; Calzada et al., 2003), contractility (Isenberg
et al., 2006b), and gene expression (Kaur et al., 2013). TSP1,
directly and indirectly, promotes platelet activation and throm-
bosis (Bonnefoy et al., 2006; Isenberg et al., 2008e). Given that
differential expression of the several TSP1 receptors can change
the outcome of its interactions with vascular cells, it is not sur-
prising that contradictory activities have been ascribed to this
protein. Early reports linked TSP1 to decreased tumor growth
through inhibitory activity on endothelial cell migration and pro-
liferation, with subsequent decreased angiogenesis (Good et al.,
1990). Conversely, in arterial smooth muscle cells (Majack et al.,
1986) and in retinal pericytes [a smooth muscle like cell associ-
ated with capillaries (Scheef et al., 2009)] TSP1 has the opposite
effect and promotes proliferation and cell hypertrophy (Wang
and Frazier, 1998). Recently, clarification of several contradic-
tory activities ascribed to TSP1 has come from the finding of
an intersection between NO signaling and this matricellular
protein. These findings have also provided increased under-
standing of sub-acute and chronic signaling events attributed
to TSP1.
REGULATION OF sGC AND cGMP BY THROMBOSPONDINS
TSP1 limits tumor growth and tumor-associated vascularization
(Isenberg et al., 2009b). This well-characterized anti-angiogenic
activity was localized to the type 1 repeat domain of TSP1
(Tolsma et al., 1993; Iruela-Arispe et al., 1999), which mediates
interaction with the cell surface receptor CD36 (Dawson et al.,
1997). TSP1 inhibited growth factor-stimulated corneal angio-
genesis in wild type (CD36+/+) mice but not in CD36−/− mice
(Jimenez et al., 2001). Conversely, in wild type mice treated with
a CD36 antibody, TSP1 binding and activation of the receptor
was blocked, which increased inflammatory-stimulated corneal
angiogenesis (Mwaikambo et al., 2006). More recently, exogenous
TSP1, the recombinant type 1 repeat protein domain of TSP1, and
a CD36-targeting peptide (based on the proposed CD36 binding
site of TSP1) all limited NO-stimulated effects including pro-
liferation and migration of vascular endothelial cells (Isenberg
et al., 2005b). TSP1 also rapidly limited NO-mediated activation
of sGC to suppress cGMP production. Exogenous TSP1 inhib-
ited sGC sensitivity to NO within 10min of treatment. Of note,
TSP1-mediated inhibition of sGC and downstream suppression
of cGMP production is not secondary to alterations in PDE activ-
ity. These data indicate that TSP1-CD36 signaling is sufficient
to limit NO-sGC signaling in endothelial cells. Arterial smooth
muscle cells and platelets also express CD36 in the cell mem-
brane. Treating cells for 10min with exogenous TSP1 inhibited
NO signaling via CD36 as well (Isenberg et al., 2006b, 2008e).
The data further suggest that (1) this inhibitory effect occurs
in a short period of time, and (2) this is an inhibitory pathway
common to all vascular cells. Dose response experiments indicate
that primary vascular cells are extremely sensitive to TSP1 with
2.2–22 pmol/L concentrations of TSP1 completely inhibiting NO
activation of sGC. Comparison with published dosages in growth
factor studies suggests TSP1 inhibition of NO may be a more
sensitive signal and may dominate in a given micro-environment
in vivo.
In a wound healing assay, skeletal muscle angiogenesis stimu-
lated by exogenous NO was potently inhibited by the addition of
exogenous TSP1 (Isenberg et al., 2005b). Surprisingly, CD36−/−
muscle explants and endothelial cells remained sensitive to TSP1-
mediated inhibition of sGC-cGMP signaling (Isenberg et al.,
2006a). The finding that CD36−/− cells were susceptible to TSP1-
mediated inhibition of NO effects suggested that an alternative
cell receptor for TSP1 may play a more important role in this
process. TSP1 was demonstrated to functionally interact with the
widely expressed cell receptor CD47 (McDonald et al., 2003).
CD47 was originally ascribed roles in mediating cell adhesion,
platelet activation, macrophage recognition of self (Oldenborg
et al., 2000) and integrin signaling (Brown and Frazier, 2001).
Our team confirmed that TSP1 binds CD47with very high affinity
(Isenberg et al., 2009a). In contrast to results in CD36−/− tissues,
NO-stimulated skeletal muscle angiogenesis in CD47−/− explants
is resistant to TSP1 inhibition (Isenberg et al., 2006a). At the level
of sGC, CD47−/− endothelial cells have higher basal and NO-
stimulated cGMP production than wild type cells. Conversely,
TSP1-mediated inhibition of basal sGC and NO-mediated acti-
vation is absent in CD47−/− endothelial and vascular smooth
muscle cells. Importantly, TSP1 inhibition of sGC activation via
CD36 requires the presence of CD47 (Isenberg et al., 2006a). TSP1
also inhibits uptake of free fatty acids via CD36, and this, in turn,
limits myristylation of Src-family kinases and downstream acti-
vation of eNOS (Isenberg et al., 2007c). Thus, concentrations
of TSP1 or TSP1 mimetic drugs such as ABT-510 sufficient to
inhibit the fatty acid translocase activity of CD36 can inhibit
sGC activation by limiting eNOS activation and subsequent pro-
duction of the physiological sGC ligand NO (Isenberg et al.,
2008f).
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At higher concentrations the thrombospondin family mem-
bers TSP1 and TSP4 can also engage CD47 to inhibit
NO-mediated sGC activation (Isenberg et al., 2009a). However,
physiological regulation of sGC activity and tissue perfusion
was not perturbed in TSP2−/− cells and null mice subjected to
ischemic injury. Nonetheless, in certain pathological situations
alternative thrombospondins, acting through CD47, may inhibit
the NO-sGC-cGMP pathway. As tissue- and time-specific expres-
sion of these proteins has been reported, this finding may be
of clinical importance. TSP1, and a TSP1-derived recombinant
domain containing the CD47 targeting portion of the protein
termed E123CaG1 both inhibit NO-mediated sGC activity by
as much as >60%, at nanomolar concentrations (Ramanathan
et al., 2011). Studies show that under ischemic challenge soft
tissue blood flow is lost in CD36−/− animals, whereas it is
preserved in CD47−/− animals (Isenberg et al., 2008c), estab-
lishing CD47 as the necessary receptor for TSP1 signaling to
regulate sGC.
Calcium has been shown to directly inhibit sGC basal func-
tion and limit ligand activation of the enzyme in vivo and in
vitro (Parkinson et al., 1999; James et al., 2009). In this context,
sGC activation by both stimulators and activators is inhibited
by TSP1 (Isenberg et al., 2008a; Miller et al., 2010a) (Figure 1).
Human endothelial cells treated with TSP1 (2.2 nmol/L) followed
by the calcium ionophore ionomycin demonstrated a decrease in
the expected sustained Ca2+ release phase. In freshly harvested
arteries, en face analysis found that TSP1 inhibited ionophore-
mediated calcium wave propagation on the endothelium mono-
layer (Bauer et al., 2010). This is in contrast to TSP1 activity in
Jurkat T cells, where both the whole protein and a recombinant
C-terminal domain(E123CaG1) that we previously demonstrated
interacts selectively with CD47 (Isenberg et al., 2009a), increased
cytosolic Ca2+ and inhibited sGC (Ramanathan et al., 2011).
Upon the interaction of TSP1 or E123CaG1 with the cell mem-
brane, intracellular Ca2+ concentrations increased to 300 nM,
which in turn activated Ca2+/ calmodulin-dependent kinase(s)
that putatively inactivated/inhibited sGC through phosphoryla-
tion at a yet to be determined residue (Agullo et al., 2005). The
inhibitory modification(s) of sGC induced by TSP1-CD47 sig-
naling is stable to disruption of the cell membrane following
treatment with E123CaG1 (Ramanathan et al., 2011). TSP1 treat-
ment also increases cytosolic Ca2+ in several non-vascular cell
types, specifically mast cells and fibroblasts, though the effect
this has on NO-sGC-cGMP signaling in these cells is not known
(Tsao and Mousa, 1995; Sick et al., 2009). This recent work
provides mechanistic insight for a CD47 antibody inhibiting
fibronectin, but not histamine-induced Ca2+ entry in endothe-
lial cells (Schwartz et al., 1993). Together these data suggest
that activated CD47 regulates a non-classical calcium channel in
vascular cells.
To date, cell culture experiments in wild type and CD47−/−
endothelial and vascular smooth muscle cells and platelets
have provided genetic confirmation that TSP1, via CD47,
inhibits both basal and NO-stimulated sGC activation (Isenberg
et al., 2006a). This process extends to a wide range of mam-
malian cells as confirmed using vascular cells from mice
(Isenberg et al., 2006a), rats (Maxhimer et al., 2009; Yao et al.,
2011), pigs (Isenberg et al., 2008d), cows (Bauer et al., 2010;
Kaur et al., 2010) and human vascular cells (Isenberg et al.,
2005b).
TSP1 INHIBITS PHARMACOLOGIC ACTIVATION OF sGC
Unwanted side effects to NO donor drugs (Rindone and Sloane,
1992) and tolerance following chronic drug exposure (Munzel
et al., 2005) have led to efforts to develop sGC stimulators and
activators that enhance NO sensitivity and do not require NO
at all for enzyme activation. Several of these agents are cur-
rently in clinical trials for treatment of cardiovascular diseases
(Evgenov et al., 2006; Stasch et al., 2011; Cannon and Pepke-Zaba,
2014). Not surprisingly, TSP1-CD47 inhibition of NO-mediated
activation of sGC raised the question of whether TSP1 also
inhibited sGC in the presence of sensitizers and activators. In
platelets, which also express CD47, a low concentration of TSP1
(2.2 nmol/L) inhibited the disaggregation stimulated by several
small molecule activators and stimulators of sGC including YC-
1, BAY 41-2272 and meso-porphyrin IX (Miller et al., 2010a).
The same concentration of TSP1 inhibited vascular smooth mus-
cle cell relaxation stimulated by these compounds. TSP1 limited
the expected increase in cGMP induced by YC1, BAY 41-2272
and PPIX, confirming that sGC was the direct target of this
effect. As these agents synergize with both NO and CO to
increase sGC activity, these data suggest TSP1 may limit bio-
gas signaling from several sources (see below). Interestingly, the
TSP1-derived CD47 activating domain E123CaG1 also inhibited
YC-1- and BAY 41-2272-mediated stimulation of sGC. This inhi-
bition could only be reversed by adding back exogenous NO
(Ramanathan et al., 2011). This finding may be of clinical rel-
evance, as NO-independent stimulators and activators of sGC
are being developed for use in diseases, including pulmonary
hypertension (Mittendorf et al., 2009), in which NO signaling
is reduced or absent (Rabinovitch, 2007; Stasch and Evgenov,
2013) and, as we have shown, TSP1-CD47 signaling concurrently
upregulated (Bauer et al., 2012).
ALTERNATIVE LIGAND ACTIVATION OF THE CD36-CD47
COMPLEX BY β-AMYLOID INHIBITS NO- AND
CHEMICAL-MEDIATED sGC STIMULATION
The secreted protein β-amyloid has been hypothesized to interact
with CD36 and CD47 (Bamberger et al., 2003; Wilkinson et al.,
2006) (Figure 1). This finding suggested that β-amyloid may act
via CD36 and CD47 to inhibit vascular cell sGC-cGMP signal-
ing. Interestingly, β-amyloid protein, and peptides derived from
the same, limited essential fatty acid uptake via CD36 (a classic
fatty acid translocase). β-amyloid peptides inhibited sGC activa-
tion by a primary NO donor and stimulation by BAY 41–2272
in several cell types including bovine endothelial cells, porcine
vascular smooth muscle cells and human T cells (Miller et al.,
2010b). The inhibitory effect was greatest in human T cells and
characterized by an IC50 in the nanomolar range. Gene silenc-
ing of CD36 attenuated, while gene silencing of CD47 abolished,
β-amyloid-mediated inhibition of sGC. Endogenous TSP1 did
not further regulate this response. Thus β-amyloid functions as
an alternative activator of the CD36-CD47 complex to potently
inhibit sGC-cGMP signaling.
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TSP1 INHIBITS OTHER BIOGAS LIGANDS AND ACTIVATORS
OF sGC
TSP1 signaling through CD47 may also modulate cGMP sig-
naling indirectly via its inhibition of hydrogen sulfide (H2S)
signaling (Figure 1). H2S can regulate NO-sGC-cGMP signaling
through regulation of NO synthesis and metabolism (Whiteman
andMoore, 2009). TSP1 acting through CD47 in T cells limits the
activation-dependent induction of the H2S biosynthetic enzymes
cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE)
(Miller et al., 2013). TSP1 also inhibits the activity of exoge-
nous H2S to activate T cells. Exogenous TSP1 inhibited H2S
responses in wild type and TSP1−/− T cells but enhanced the
same responses in CD47−/− T cells. Engaging CD47 using a
CD47-binding peptide derived from TSP1 similarly inhibited sig-
naling. TSP1 signaling via CD47 thereby blocks the autocrine
function of H2S to increase T cell activation (Miller et al., 2012).
Several mechanisms have been proposed through which H2S
can regulate NO-sGC-cGMP signaling including regulation of
NO synthesis and metabolism (reviewed in Whiteman and
Moore, 2009). In pancreatic acini, H2S was found to increase
Ca2+ levels (Moustafa and Habara, 2014). The elevated calcium
levels were shown to increase NO synthesis, consistent with the
known calcium regulation of eNOS. However as noted above,
altered calcium levels can also directly modulate sGC activity.
In mice lacking the H2S biosynthetic enzyme CSE, the reduced
H2S levels were associated with increased left ventricular hyper-
trophy after transverse aortic constriction (Kondo et al., 2013).
H2S signaling was shown to stimulate VEGF production and
Akt-dependent eNOS phosphorylation in this model of pressure
overload heart failure, which led to increased cGMP synthesis.
Finally, H2S induced increased expression of eNOS and iNOS in
the vessel walls of treated mice. The anti-thrombotic activity of
H2S in these mice was partially reversed by administration of the
general nitric oxide synthase inhibitor L-NG-nitroargininemethyl
ester (L-NAME) (Kram et al., 2013). A similar induction of eNOS
expression by H2S was reported in rat corpus cavernosum (Meng
et al., 2013).
TSP1 CONTROLS UPSTREAM AND DOWNSTREAM
REGULATION OF THE sGC-cGMP AXIS
Loss of sGC-cGMP signaling in endothelial cells could be caused
by direct inhibition of sGC and/or proximal inhibition of NO
production at the level of the eNOS. Wild type endothelial cells
that express both TSP1 and CD47 display decreased cGMP pro-
duction compared to CD47−/− cells after stimulation with the
eNOS agonist acetylcholine, while treating human endothelial
cells with TSP1 inhibited eNOS-mediated production of NO
(Bauer et al., 2010). This in vitro effect is confirmed in the
whole animal as phosphorylation of the key activity-associated
eNOS residue serine 1117 is increased in vascular tissues from
TSP1−/− mice compared to wild type. In endothelial cells this is
mediated by CD47-dependent inhibition of VEGFR2 phospho-
rylation (Kaur et al., 2010) (Figure 1), which in turn activates
Akt to phosphorylate eNOS. TSP1/CD47 signaling also inhibits
Src activation, which as mentioned above can inhibit sGC via
phosphorylation. Further redundancy in the TSP1-CD47 axis
was found in studies of the downstream cGMP-activated kinase
(PKG). Phosphorylation of this enzyme can be stimulated in
a sGC-independent fashion with the cell permeable analogue
8-bromo-cGMP, and TSP1 inhibits this process (Isenberg et al.,
2007a, 2008e). Thus TSP1 redundantly suppresses sGC-cGMP
signaling by limiting the upstream production of the sGC lig-
and NO and by limiting the downstream activation of PKG by
cGMP. This later effect is particularly important as it suggests that
therapeutic strategies based on NO pro-drugs such as nitrite and
NO-independent stimulators of sGC, though relieving inhibition
at the level of sGC, cannot overcome upstream and downstream
pathway inhibition. Therapeutically these findings imply that the
combinatorial approach of NO-independent stimulation of sGC
and a CD47 signaling blocker may be the most efficient man-
ner to enhance NO-sGC-cGMP-PKG signaling under the chronic
conditions of cardiovascular disease.
MATRICELLULAR PROTEIN TSP1 DIRECTLY STIMULATES
ROS PRODUCTION TO FURTHER INHIBIT sGC-cGMP
SIGNALING
Cardiovascular disease is characterized by overproduction of
pathologic of ROS including superoxide(O·−2 ) and hydrogen per-
oxide (H2O2) that in turn modify proteins and adversely alter
their function (Chen and Keaney, 2012). Conversely, inhibitors of
the enzymatic sources of this pathologic ROS are under develop-
ment for possible therapeutic advantage (Cifuentes and Pagano,
2006). ROS is well known to limit physiologic NO-sGC-cGMP
signaling (see above). Hydrogen peroxide induces specific tyro-
sine phosphorylation of the β1 but not of the α1 subunit of
sGC and this may alter enzyme activity (Meurer et al., 2005).
ROS can also adversely impact gene function. Treating VSMC
with H2O2 significantly decreased protein levels of the α and
β subunits of sGC and inhibited SNP-stimulated cGMP forma-
tion (Gerassimou et al., 2007). ROS further limits physiologic
NO-sGC-cGMP signaling by reacting with NO (Figure 1). In
endothelial cells introduction of intracellular- or extracellular-
generated O·−2 during NO generation resulted in a concomitant
increase in oxidative intermediates with a decrease in steady-state
NO concentrations (Thomas et al., 2006). Finally, a number of
mechanisms exist that serve to buffer and degrade pathologic
ROS. Loss of these ROS suppressing enzymatic systems is noted
in cardiovascular disease and is associated with increased sGC
S-nitrosylation and decreased activity (Choi et al., 2011).
Recently TSP1 has been linked to cardiovascular disease in
people. Elevated plasma TSP1 levels are correlated with vasooc-
clusive crises (Novelli et al., 2012) and peripheral vascular disease
(Smadja et al., 2011); tissue TSP1 protein and mRNA levels are
overexpressed in the leg muscles of patients with ischemic periph-
eral vascular disease (Favier et al., 2005), and single nucleotide
polymorphisms of TSP1 and TSP4 are associated with higher
rates of early myocardial infarction (Narizhneva et al., 2004;
Stenina et al., 2005). Given the known roles ROS plays in cardio-
vascular disease, this suggested that TSP1 may directly participate
in ROS production. Hypoxic challenge of human pulmonary
arterial endothelial cells increases TSP1 andO·−2 production while
treatment with a CD47 antagonist antibody suppresses this effect
(Bauer et al., 2012). Ligation of B-cell CD47 induces mitochon-
drial dysfunction and ROS production, likely as part of a cell
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death process (Mateo et al., 2002). Treatment of vascular smooth
muscle cells with a low concentration of TSP1 (2.2 nmol/L)
increases O·−2 production within 1 h (Csanyi et al., 2012). In
endothelial-denuded arterial rings TSP1 treatment increased CM
radical formation as measured with electron paramagnetic reso-
nance. Studies employing pharmacologic inhibitors of enzymatic
ROS, siRNA knock down and endothelial free arterial rings from
the respective null mice all indicate the source of this O·−2 is likely
the NADPH oxidase 1 (Nox1). TSP1 is a more potent stimula-
tor of ROS compared to the classic activators phorbol myristate
acetate and angiotensin II. The CD47 targeting peptide 7N3 that
contains the Val-Val-Met sequence also increased VSMCO·−2 pro-
duction (Csanyi et al., 2012). Conversely, treating VSMC with
a morpholino oligonucleotide to suppress CD47 protein expres-
sion (Isenberg et al., 2008d) or an antagonist antibody to block
TSP1 binding to CD47, ablated TSP1-mediated O·−2 production
(Csanyi et al., 2012). Thus TSP-CD47 stimulates Nox-derived O·−2
production in vascular smooth muscle cells.
TSP1 is currently the only identified soluble ligand of CD47.
However, CD47 can be ligated by the cell membrane protein
SIRP-α (Vernon-Wilson et al., 2000). In VSMC, SIRPα has
been linked to insulin like growth factor-stimulated ROS pro-
duction (Xi et al., 2013). New studies in VSMC found that
TSP1-mediated O·−2 production was abrogated in cells treated
with a SIRPα morpholino oligonucleotide or a SIRP-α blocking
antibody (Yao et al., 2014). Likewise, in renal tubular epithe-
lial cells (rTEC), that we have shown expresses CD47 (Rogers
et al., 2012), TSP1 (2.2 nmol/L) treatment increased O·−2 pro-
duction which was blocked by treatment with a SIRPα oligonu-
cleotide morpholino and a SIRP-α antagonist antibody (Yao
et al., 2014). Together these data show that soluble TSP1 can
potently stimulate pathologic O·−2 production in vascular and
epithelial cells and that this was mediated by interactions with
both receptors CD47 and SIRP-α. It is likely that the TSP1-
SIRPα interaction does not extend to other secreted proteins
such as β-amyloid as the fibrillar form of this protein did not
inhibit CD47 binding to a SIRP-α-Fc fusion protein (Miller et al.,
2010b).
TSP1-CD47 REGULATION OF sGC-cGMP SIGNALING HAS
EFFECTS ON BLOOD FLOW
An immediate effect of sGC activation in arterial smooth muscle
cells is uncoupling of actin-myosin interaction and relaxation of
the cellular contractile response. This process is central to pro-
motion of blood flow through the vasculature. TSP1 treatment
blocks NO- and sodium nitroprusside (SNP)-mediated activation
of sGC and subsequent dephosphorylation of myosin light chain
2 (the kinase responsible for vasoconstriction) while increas-
ing immuno-reactive F-actin in cultured VSMC (Isenberg et al.,
2007a). In vitro studies of VSMC contraction in collagen matrix
demonstrated that TSP1 inhibits both NO- and SNP-stimulated
relaxation (Isenberg et al., 2007a). In arterial ring myography
bioassays, TSP1 (at 0.22 nmol/L) and the CD47-targeting domain
E123CaG1 (at 2.2 nmol/L) inhibit endothelial-dependent vasodi-
lation (Bauer et al., 2010). CD47−/− arterial rings are immune
to TSP1-mediated inhibition of vasodilation while exogenous
TSP1 continues to inhibit Ach-mediated vasodilation in TSP1−/−
arterial rings (Bauer et al., 2010). In soft tissues and visceral
organs TSP1 inhibits blood flow following ischemia reperfu-
sion injury (IRI) (Isenberg et al., 2008b; Csanyi et al., 2012)
while TSP1−/− (Isenberg et al., 2007a, 2008c) and CD47−/−
animals (Rogers et al., 2012) display enhanced blood flow fol-
lowing ischemia and IRI. Both eNOS and sGC subunit protein
expression levels were comparable in vessels from wild type,
TSP1−/− and CD47−/− mice (Bauer et al., 2010) indicating
these functional responses are secondary to the acute inhibitory
activity of TSP1, via CD47, on the canonical NO-sGC-cGMP
pathway.
Based on the above and other work these functional responses
may also be, in part, secondary to alternative mechanisms. In
VSMC, TSP1 inhibits cAMP-mediated suppression of F-actin
organization and inhibits forskolin-stimulated vasodilation of
endothelial-free arterial rings (Yao et al., 2011). Alternatively,
results in cell cultures suggest that TSP1, via CD47 and/or SIRP-α,
could control blood vessel dilation and blood flow through stim-
ulating pathologic ROS. In endothelial-free arterial rings gene
knock done of Nox1 abrogated TSP1-mediated inhibition of SNP-
stimulated vasodilation (Csanyi et al., 2012). Likewise treatment
of arterial rings with the ROS scavenger Tempol corrected TSP1-
mediated inhibition of vasodilation (Yao et al., 2014). In animals,
an intravenous TSP1 bolus impaired restoration of blood flow fol-
lowing short term (<1 h) ischemia and this was ameliorated by
gene silencing of Nox1 or treatment with a CD47 antagonist anti-
body (Csanyi et al., 2012). Finally, in animals a SIRP-α antagonist
antibody, that blocked TSP1-mediated O·−2 production, enhanced
blood flow restoration following 20min of renal ischemia (Yao
et al., 2014).
Null vascular cells display enhanced sGC-cGMP signaling.
Employing telemetry monitoring of central blood pressure,
TSP1−/− and CD47−/− mice were found to have a widened pulse
pressure (Isenberg et al., 2009c), while CD47−/− mice were sig-
nificantly hypotensive at rest. Similarly, TSP1−/− and CD47−/−
animals undergo greater flux in mean arterial blood pressure
following an exogenous NO challenge compared to wild type
(Isenberg et al., 2009c). It is not clear if variation in autonomic
nervous system function plays a role in any of these findings as
TSP1−/− and CD47−/− mice show greater sensitivity to post-
ganglionic blockade with a greater drop inMAP compared to wild
type animals (Isenberg et al., 2009c). In the peripheral micro-
circulation thermal and NO-stimulated flux in cutaneous blood
flow is also greater in TSP1−/− and CD47−/− mice (Rogers et al.,
2013).
Under the stress of chronic hypoxia (10% FiO2 for 3 weeks)
TSP1−/− mice maintained a more normal cardiovascular profile
compared to wild type animals with less change in right ven-
tricular systolic pressure, less right ventricular hypertrophy and
less pulmonary vascular smooth muscle cell hyperplasia. This
observation was further associated with less pulmonary ROS pro-
duction (Bauer et al., 2012). TSP1−/− and CD47−/− mice show
improved blood flow and less tissue injury in the hind limb com-
pared to wild type following femoral artery ligation and this
benefit in tissue perfusion persists with ageing (Isenberg et al.,
2007b). However, wild type and TSP2−/− mice display compa-
rable amounts of tissue loss in ischemic soft tissue flaps and
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comparable diminution in hind limb blood flow after femoral
artery ligation (Isenberg et al., 2009a). A lack of a tissue sur-
vival and blood flow advantage in TSP2−/− mice is consistent
with vascular cell culture experiments where the recombinant
TSP2 domain inhibited NO-mediated sGC activation modestly
(Isenberg et al., 2009a). This is in contrast to results in TSP1-
TSP2−/− mice that show enhanced revascularization following
femoral artery ligation compared to wild type animals (Kopp
et al., 2006; MacLauchlan et al., 2011).
TSP1-CD47 REGULATION OF sGC-cGMP SIGNALING HAS
THERAPEUTIC IMPLICATIONS
TSP1 accounts for approximately 50% of the preformed pro-
tein within platelet alpha granules. TSP1 antibodies have shown
some effect in tissue models of ischemia (Isenberg et al., 2007d,
2008d). However, it is theoretically more efficient to target CD47.
In a human cell line a CD47 antagonist antibody blocks TSP1-
mediated inhibition of sGC. Treating full thickness skin grafts
with a CD47 antagonist antibody increased graft healing rates in
an animal model (Isenberg et al., 2008c). Antisense suppression
of CD47 increased sGC-cGMP signaling in VSMC and ischemic
tissue survival. In ApoE null mice that demonstrate an acceler-
ated vasculopathy, blocking CD47 expression with morpholino
oligonucleotide enhanced ischemic soft tissue survival (Isenberg
et al., 2007b). In a severe tissue ischemia model, treating ani-
mals with a CD47 antagonist antibody in combination with an
NO pro-drug provided additive benefits increasing tissue sur-
vival by 100% compared to treatment with the NO pro-drug
alone (Isenberg et al., 2009d). This later result is clinically rele-
vant as nitrite is being developed for use in humans (see NIH
clinical trials NCT01409122 and NCT01715883 among others).
Likewise, interrupting matricellular activation of CD47 enhances
liver (Isenberg et al., 2008b) and kidney survival (Rogers et al.,
2012) following IRI and ablates pulmonary arterial hyperten-
sion in rodents (Bauer et al., 2012). In 5th order pulmonary
arteries from the lungs of a patient undergoing transplant for
end-stage pulmonary arterial hypertension the TSP1-CD47 axis
was induced while NO-dependent and independent vasodila-
tion was almost abolished (Rogers et al., 2013; Published online
Feb 3, 2014), confirming in human disease activation of the
TSP1-CD47 inhibitory axis is concurrent with loss on NO-
sGC-cGMP signaling. Taken together basic and clinical studies
suggest that a more comprehensive way to treat chronic car-
diovascular disease would be to combine sGC activation with
disruption of the TSP1-CD47 pathway as a novel therapeutic
strategy.
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